Nuvation Bio Inc. (NUVB) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to NuvationBio's third quarter 2025 financial result and corporate update call. Today's call is being recorded and a replay will be available. All participants are currently in a listen only mode. A brief question and answer session will follow the prepared remarks. Now I'd like to turn the call over to J.R. Devita, Executive Director of Corporate Development and Investor Relations at NuvationBio. Please go ahead. Thank you and good afternoon, everyone. Welcome to the innovation bio third quarter 2025 earnings conference call. Earlier today, we released financial results for the quarter ending September 30 2025 and provided a business update. The press release is available on the investor section of our website at innovation bio.com. And a recording of this conference call will also be available on our website following its completion. I'd like to remind you that today's call includes forward-looking statements, including statements about the therapeutic and commercial potential of Iptrosi and Sapucitinib, the components of our anticipated product revenue, expected milestone payments, and our cash runway. Because such statements deal with future events and are subject to many risks and uncertainties, actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our annual report on Form 10-K and our quarterly reports on Form 10-Q that are filed with the US Securities and Exchange Commission. Joining me on today's call to discuss our quarterly results are our Founder, President, and Chief Executive Officer, Dr. David Hung, our Chief Commercial Officer, Colleen Sjogren, and our Chief Financial Officer, Philippe Sauvage. David will provide an overview of our key ...